|
|
Small Molecule Activators of Pro-apoptotic BAX for Cancer Therapy
|
5R01CA178394-05
|
$346,525
|
$173,263
|
GAVATHIOTIS, EVRIPIDIS
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Core Support for Cancer Center
|
3P30CA013330-45S1
|
$3,646,138
|
$364,614
|
GOLDMAN, ISRAEL
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
PI3K Isoform Dependence in Adult Hematopoiesis and Myeloid Leukemia
|
5R01CA196973-03
|
$415,736
|
$415,736
|
GRITSMAN, KIRA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
5F30CA210539-03
|
$44,524
|
$22,262
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Investigating the role of Nol3 in normal and malignant hematopoiesis
|
1F30CA217063-01A1
|
$49,524
|
$49,524
|
PISZCZATOWSKI, RICHARD
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Mechanisms of Formation and Progression of Preleukemic Stem Cells
|
5R01CA217092-02
|
$397,371
|
$397,371
|
STEIDL, ULRICH
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Identification and targeting of pathways separating healthy stem cell aging from malignant transformation
|
1R01CA230756-01
|
$382,013
|
$382,013
|
WILL, BRITTA
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
|
Enhanced Training and Mentorship of Hematologic Oncologists
|
2R25CA168526-06
|
$306,150
|
$101,030
|
SUNG, LILLIAN
|
AMERICAN SOCIETY OF HEMATOLOGY
|
|
|
Create three-member project team to refine commercialization plans for AML-Mutation Counter, a tool to detect residual and recurrent leukemia.
|
3R41CA213690-01S1
|
|
$0
|
KAUFMANN, WILLIAM
|
ASYSTBIO LABORATORIES, LLC
|
|
|
Genetic Analysis of Myeloproliferative Disease
|
5R01CA076167-15
|
$307,800
|
$307,800
|
COWELL, JOHN
|
AUGUSTA UNIVERSITY
|
|
|
Role of heat shock factors (Hsfs) in tumorigenesis
|
5R01CA132640-17
|
$270,000
|
$270,000
|
MIVECHI, NAHID
|
AUGUSTA UNIVERSITY
|
|
|
Proteogenomic Translational Research Center for Clinical Proteomic
|
5U01CA214116-02
|
$1,372,508
|
$1,372,508
|
RODLAND, KARIN
|
BATTELLE PACIFIC NORTHWEST LABORATORIES
|
|
|
Integrative Molecular Epidemiology of Neurocognitive Outcomes in Acute Lymphoblastic Leukemia
|
1K07CA218362-01A1
|
$166,043
|
$166,043
|
BROWN, AUSTIN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
A Mouse Model of DNMT3A-Associated Hematologic Malignancy
|
5R01CA183252-05
|
$533,845
|
$533,845
|
GOODELL, MARGARET
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Mechanisms of KLF4 suppression in pediatric leukemia
|
5R01CA207086-02
|
$370,641
|
$370,641
|
LACORAZZA, DANIEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Metabolic Regulation in Leukemia-Initatiating Cells
|
5R01CA193235-04
|
$462,191
|
$462,191
|
NAKADA, DAISUKE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S1
|
$118,875
|
$9,510
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S2
|
$249,997
|
$20,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-12S3
|
$125,004
|
$10,000
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-12
|
$3,203,119
|
$256,250
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
DEFINING THE ROLE OF DOT1L IN DNMT3A-MUTANT LEUKEMIA
|
5K08CA201611-02
|
$162,148
|
$162,148
|
RAU, RACHEL
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Using Stat3 Signaling Profiles to Understand Chemotherapy Resistance in AML
|
5R01CA175026-05
|
$379,294
|
$379,294
|
REDELL, MICHELE
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Human natural killer cells: Advancing biology and clinical applications
|
7R35CA210087-02
|
$992,214
|
$496,107
|
CALIGIURI, MICHAEL
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Impact of aging on the outcomes of a mouse model of chronic myeloid leukemia
|
4UH3CA213385-03
|
$87,498
|
$87,498
|
CHEN, WENYONG
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Epigenetic mechanisms for oncogene silencing in MLL-rearranged leukemia
|
5R00CA197498-05
|
$249,000
|
$249,000
|
CHEN, CHUN-WEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
The role and functional mechanism of TET1 in MLL-rearranged leukemia
|
5R01CA178454-07
|
$369,725
|
$369,725
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
The role and mechanism of FTO in leukemogenesis and drug response
|
5R01CA214965-03
|
$444,571
|
$444,571
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Potential therapeutic implications of targeting miR-150 in acute myeloid leukemia
|
7R01CA182528-06
|
$392,355
|
$392,355
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting TET1 signaling to treat acute myeloid leukemia
|
7R01CA211614-02
|
$475,560
|
$475,560
|
CHEN, JIANJUN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
CMVPepVax to Protect HCT Recipients from Cytomegalovirus Infection
|
5R01CA181045-05
|
$721,537
|
$721,537
|
DIAMOND, DON
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Image-guided irradiation safely intensifies HSCT regimen for refractory leukemia
|
5R01CA195519-03
|
$238,425
|
$238,425
|
FORMAN, STEPHEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting Transcriptional Regulators for Immunotherapy of Acute Myeloid Leukemia
|
5R01CA213131-02
|
$430,377
|
$430,377
|
KORTYLEWSKI, MARCIN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
HDAC8 Mediated Regulation of Acute Myeloid Leukemia Pathogenesis and Maintenance
|
5R01CA178387-05
|
$317,475
|
$317,475
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting microRNAs to eradicate leukemia stem cells
|
5R01CA205247-02
|
$450,769
|
$450,769
|
KUO, YA-HUEI
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Biologic and Therapeutic Significance of miR-155 in AML
|
5R01CA201184-03
|
$549,553
|
$549,553
|
MARCUCCI, GUIDO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Optimizing Busulfan: Efficacy Toxicity and Pharmacometabolomics
|
5R01CA182963-06
|
$515,038
|
$515,038
|
MCCUNE, JEANNINE
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeted activation of autoimmune checkpoints in B cell malignancies
|
5R01CA157644-09
|
$410,875
|
$410,875
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
CD25-mediated feedback control of BCR-signaling and its oncogenic mimics
|
5R01CA213138-02
|
$395,738
|
$134,551
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Metabolic basis of B cell lineage leukemia relapse
|
5R35CA197628-03
|
$1,035,561
|
$1,035,561
|
MUSCHEN, MARKUS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
2P30CA033572-35
|
$2,543,187
|
$762,956
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-34S3
|
$865,000
|
$259,500
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Cancer Center Support Grant
|
3P30CA033572-35S1
|
$43,750
|
$13,125
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Novel RNA-Directed Therapy for the Treatment of Acute Myeloid Leukemia
|
5R01CA201496-03
|
$479,954
|
$479,954
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Mentored Clinical Scientist Research Career Development Award (Parent K08)
|
1K08CA234394-01
|
$249,042
|
$249,042
|
SLAVIN, THOMAS
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Targeting the ARHGAP25 pathway in acute myelogenous leukemia stem cells
|
5K08CA201591-02
|
$169,560
|
$169,560
|
WANG, LEO
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
PD-L1 interacts with CD80 and PD-1 to regulate GVHD and GVL activity
|
1R01CA228465-01
|
$404,275
|
$404,275
|
ZENG, DEFU
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
|
Personalized vaccine for patients with AML
|
5R01CA212649-02
|
$721,179
|
$721,179
|
AVIGAN, DAVID
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Determining the role of DNMT-interacting RNAs in myeloid disorders
|
5R00CA188595-04
|
$249,000
|
$249,000
|
DI RUSCIO, ANNALISA
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Regulatory role of long noncoding RNAs in normal and cancer cells
|
5R50CA211304-02
|
$261,280
|
$261,280
|
EBRALIDZE, ALEXANDER
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting PML for Leukemia Therapy
|
5R01CA142874-08
|
$457,619
|
$457,619
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Total relevant funding to Leukemia for this search: $258,284,568
|
